Wall Street analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to report $17.22 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Seres Therapeutics’ earnings. The highest sales estimate is $23.43 million and the lowest is $11.00 million. Seres Therapeutics reported sales of $23.02 million in the same quarter last year, which suggests a negative year over year growth rate of 25.2%. The firm is scheduled to report its next earnings report on Wednesday, November 14th.
According to Zacks, analysts expect that Seres Therapeutics will report full-year sales of $30.02 million for the current fiscal year, with estimates ranging from $24.60 million to $35.44 million. For the next financial year, analysts anticipate that the business will report sales of $21.02 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. The company had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $5.22 million. Seres Therapeutics had a negative return on equity of 256.24% and a negative net margin of 264.31%.
Several brokerages recently issued reports on MCRB. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 4th. Bank of America cut Seres Therapeutics from a “neutral” rating to an “underperform” rating in a research report on Friday, August 3rd. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 1st. Finally, BidaskClub cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $17.25.
In other Seres Therapeutics news, insider Roger Pomerantz sold 32,336 shares of the business’s stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $9.12, for a total value of $294,904.32. Following the transaction, the insider now owns 243,670 shares of the company’s stock, valued at $2,222,270.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP John G. Aunins sold 14,279 shares of the business’s stock in a transaction on Sunday, July 15th. The stock was sold at an average price of $8.10, for a total value of $115,659.90. Following the completion of the transaction, the executive vice president now directly owns 160,927 shares in the company, valued at approximately $1,303,508.70. The disclosure for this sale can be found here. In the last three months, insiders sold 189,287 shares of company stock worth $1,727,755. Insiders own 37.10% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Seres Therapeutics in the second quarter worth $117,000. Bank of America Corp DE boosted its position in Seres Therapeutics by 175.0% in the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 23,222 shares during the last quarter. A.R.T. Advisors LLC boosted its position in Seres Therapeutics by 141.3% in the first quarter. A.R.T. Advisors LLC now owns 45,952 shares of the biotechnology company’s stock worth $337,000 after purchasing an additional 26,909 shares during the last quarter. Chicago Equity Partners LLC purchased a new position in Seres Therapeutics in the second quarter worth $415,000. Finally, Alps Advisors Inc. boosted its position in Seres Therapeutics by 21.0% in the first quarter. Alps Advisors Inc. now owns 54,359 shares of the biotechnology company’s stock worth $399,000 after purchasing an additional 9,448 shares during the last quarter. 78.04% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ:MCRB opened at $7.80 on Friday. The company has a market cap of $326.57 million, a P/E ratio of -3.53 and a beta of 0.54. The company has a debt-to-equity ratio of -0.61, a quick ratio of 2.76 and a current ratio of 2.76. Seres Therapeutics has a 12-month low of $6.65 and a 12-month high of $17.42.
About Seres Therapeutics
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).
Recommended Story: Outstanding Shares
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.